Adjuvant chemotherapy intensity and prognosis in completely resected high-grade neuroendocrine lung carcinoma: a post hoc analysis of JCOG1205/1206

Gynecologic Cancer

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial

★ 3 Recommended and commented by Dr Andreas Müller, Faculty Member

★ 1 Recommended by Prof. Dr Beat Thürlimann, Faculty Member

Lancet Oncol

Post CCB, de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Leary A, Ottevanger PB, McCormack M, Khaw P, D'Amico R, Fyles A, Chargari C, Kitchener HC, Do V, Lissoni A, Provencher D, Genestie C, Nijman HW, Whitmarsh K, Jürgenliemk-Schulz IM, Feeney A, Lutgens LCHW, Bouma J, Leon-Castillo A, Nout RA, Putter H, Bosse T, Creutzberg CL

doi: 10.1016/S1470-2045(25)00379-1

RECOMMENDED

Breast Cancer

Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial

★ 1 Recommended by Prof. Dr Beat Thürlimann, Faculty Member

Lancet Oncol

Yuan J, Bi XW, Hua X, Huang H, Cai L, Zhao L, Chen QJ, Chen XX, Wang XL, Lin Y, Zhang AQ, Zhong YY, Xu F, Huang JJ, An X, Shi YX, Wang X, Wang SS, Xue C, Yuan ZY

doi: 10.1016/S1470-2045(25)00545-5

Lung, Respiratory and Thoracic Cancer

Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials

Lung Cancer

Guerrera F, Gallina FT, Balzani E, Ambrosi F, Federico AD, Faccioli E, Facheris G, Ferrara R, Ferro A, Filipello F, Giusti R, Greco C, Mammana M, Marinelli D, Nuccio A, Pittaro A, Sepulcri M, Viscardi G, Bertoglio P

doi: 10.1016/j.lungcan.2025.108760

Lung, Respiratory and Thoracic Cancer

The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study

Lung Cancer

Rolfo C, Gerber DE, Kotecha R, Ward JP, Akerley W, Weiss L, Naveh A, Shapira N, Leal T, Langer CJ, LUNAR study investigators

doi: 10.1016/j.lungcan.2025.108802

Gastrointestinal Cancer

Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis

J Clin Oncol

Raimondi A, Tinè G, Ballhausen A, Lonardi S, Tougeron D, Ricagno G, Nappo F, De Vita F, Nankivell M, Cunningham D, Lee J, Kang WK, Cheong JH, Choi YY, Randon G, Prisciandaro M, Pircher CC, Manca P, Ambrosini M, Fazio R, Bergamo F, Piessen G, Smyth EC, Modest DP, Miceli R, André T, Pietrantonio F

doi: 10.1200/JCO-25-00447

Lung, Respiratory and Thoracic Cancer

Peri-operative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: final analysis of the randomized RATIONALE-315 trial

Ann Oncol

Wang C, Wang W, Liu H, Chen Q, Chen C, Liu L, Zhang P, Zhao G, Yang F, Han G, Yu B, Yang Y, Chen H, Jiang J, Tan L, Xu S, Mao N, Hu J, Zhang L, Zhang Z, Yao B, Wang S, Leaw S, Naicker K, Zheng W, Yu C, Yue D, RATIONALE-315 investigators

doi: 10.1016/j.annonc.2025.11.017

Lung, Respiratory and Thoracic Cancer

Surgical results after neoadjuvant nivolumab and platinum-based chemotherapy for resectable lung cancer. A multicentre European real clinical practice analysis

Eur J Cardiothorac Surg

Brunelli A, Mariolo A, Aigner C, De Antonio DG, Jimenez M, Hemead H, Hoffman R, Lodhia J, Nardini M, Mattioni G, Sinn K, Hoda MA, Novoa N, Davila GR, Gomez-Hernandez MT, Rivas-Duarte C, Bhatnagar P, Clarke K, Escriu C, Fakih O, Franks K, Bouaziz K, Calvo V, Sereno M, Provencio M, Girard N, Shackcloth M

doi: 10.1093/ejcts/ezaf343

Gastrointestinal Cancer

Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis

J Natl Cancer Inst

Lopez-Lopez V, Hasse T, Houben P, Frey MC, Rangelova E, Genova L, Malleo G, Lionetto G, Lee SH, Abdurakhmonov S, Patel SH, Wilson GC, Ahmad SA, Schmocker RK, Lüthy M, Fritsch R, Palm RF, Hoffe SE, He J, Gordon-Weeks A, Lakha A, Pu N, Liu L, Owuor S, Sánchez-Velazquez P, Ielpo B, Beltrán P, Pérez-Benito MJ, Alonso IJ, Nutu A, Sobirov J, Zafra GM, Robles-Campos R, Pawlik TM, Pascher A, Yoo C, Oberholzer J, Eshmuminov D

doi: 10.1093/jnci/djag235

Genitourinary Cancer

Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age

Eur J Cancer

Shore ND, De Giorgi U, Kalac M, Tang Y, Croitoru R, Rosales M, Huynh MJ, de Jong IJ, Evans CP, Carcano FM, Freedland SJ

doi: 10.1016/j.ejca.2025.116110

Related content

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial

Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial

Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials

The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study

Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis

Peri-operative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: final analysis of the randomized RATIONALE-315 trial

Surgical results after neoadjuvant nivolumab and platinum-based chemotherapy for resectable lung cancer. A multicentre European real clinical practice analysis

Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis

Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age